Avadel Net Invested Capital vs Capital Surpluse Analysis
AVDL Stock | USD 15.49 0.45 2.82% |
Avadel Pharmaceuticals financial indicator trend analysis is way more than just evaluating Avadel Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Avadel Pharmaceuticals is a good investment. Please check the relationship between Avadel Pharmaceuticals Net Invested Capital and its Capital Surpluse accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment.
Net Invested Capital vs Capital Surpluse
Net Invested Capital vs Capital Surpluse Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Avadel Pharmaceuticals Net Invested Capital account and Capital Surpluse. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Avadel Pharmaceuticals' Net Invested Capital and Capital Surpluse is 0.59. Overlapping area represents the amount of variation of Net Invested Capital that can explain the historical movement of Capital Surpluse in the same time period over historical financial statements of Avadel Pharmaceuticals PLC, assuming nothing else is changed. The correlation between historical values of Avadel Pharmaceuticals' Net Invested Capital and Capital Surpluse is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Invested Capital of Avadel Pharmaceuticals PLC are associated (or correlated) with its Capital Surpluse. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Surpluse has no effect on the direction of Net Invested Capital i.e., Avadel Pharmaceuticals' Net Invested Capital and Capital Surpluse go up and down completely randomly.
Correlation Coefficient | 0.59 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Capital Surpluse
Most indicators from Avadel Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Avadel Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. At this time, Avadel Pharmaceuticals' Selling General Administrative is quite stable compared to the past year. Issuance Of Capital Stock is expected to rise to about 153.4 M this year, although the value of Discontinued Operations will most likely fall to about 4.2 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 9.9M | 12.3M | 9.9M | 10.4M | Depreciation And Amortization | 979K | 4.8M | 1.8M | 1.7M |
Avadel Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Avadel Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Avadel Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 151.4M | 311.6M | 247.3M | 132.8M | 261.1M | 138.0M | |
Short Long Term Debt Total | 124.7M | 130.5M | 145.0M | 131.0M | 35.4M | 38.3M | |
Other Current Liab | 3.9M | 5.2M | 5.3M | 9.3M | 24.5M | 15.3M | |
Total Current Liabilities | 36.0M | 15.1M | 21M | 55.8M | 36.9M | 29.7M | |
Total Stockholder Equity | (29.2M) | 162.3M | 78.2M | (21.1M) | 87.7M | 47.1M | |
Property Plant And Equipment Net | 4.2M | 3.0M | 2.9M | 2.6M | 3.2M | 3.0M | |
Net Debt | 114.9M | 58.8M | 94.3M | 57.0M | 4.2M | 4.0M | |
Retained Earnings | (391.2M) | (384.2M) | (447.8M) | (585.2M) | (745.5M) | (708.2M) | |
Accounts Payable | 6.1M | 2.9M | 7.7M | 7.9M | 11.4M | 6.3M | |
Cash | 9.8M | 71.7M | 50.7M | 74.0M | 31.2M | 28.3M | |
Non Current Assets Total | 69.1M | 48.2M | 54.8M | 31.9M | 126.9M | 133.3M | |
Non Currrent Assets Other | 39.3M | 24.9M | 33.8M | (60.0M) | 10.2M | 7.4M | |
Cash And Short Term Investments | 64.2M | 221.4M | 157.2M | 96.5M | 105.1M | 72.6M | |
Net Receivables | 10.4M | 3.3M | 2.4M | 2.2M | 13.4M | 9.7M | |
Common Stock Shares Outstanding | 37.4M | 54.9M | 58.5M | 60.1M | 80.2M | 84.2M | |
Liabilities And Stockholders Equity | 151.4M | 311.6M | 247.3M | 132.8M | 261.1M | 138.0M | |
Non Current Liabilities Total | 144.7M | 134.3M | 148.0M | 98.1M | 136.5M | 143.4M | |
Inventory | 6.2M | 4.8M | 3.6M | 0.0 | 10.4M | 10.9M | |
Other Current Assets | 4.3M | 38.7M | 32.8M | 2.1M | 5.3M | 5.6M | |
Other Stockholder Equity | 384.4M | 566.9M | 549.3M | 589.8M | 855.5M | 898.2M | |
Total Liab | 180.6M | 149.4M | 169.0M | 153.9M | 173.4M | 90.9M | |
Property Plant And Equipment Gross | 10.6M | 8.2M | 2.9M | 2.6M | 14.0M | 12.4M | |
Total Current Assets | 82.4M | 263.5M | 192.5M | 100.8M | 134.2M | 91.1M | |
Accumulated Other Comprehensive Income | (22.8M) | (21.1M) | (23.9M) | (26.3M) | (23.2M) | (22.0M) | |
Short Term Debt | 645K | 474K | 900K | 38.6M | 934K | 887.3K | |
Common Stock Total Equity | 427K | 429K | 583K | 586K | 527.4K | 501.0K | |
Common Stock | 429K | 583K | 586K | 628K | 898K | 853.1K | |
Other Liab | 20.6M | 4.2M | 3.9M | 5.7M | 6.6M | 6.3M | |
Current Deferred Revenue | 114K | 25.4M | 6.5M | 7.2M | 8.2M | 4.2M | |
Other Assets | 39.2M | 28.4M | 35.0M | 12.6M | 14.4M | 10.2M | |
Long Term Debt | 121.7M | 128.2M | 142.4M | 91.6M | 105.4M | 110.6M | |
Property Plant Equipment | 544K | 359K | 285K | 2.6M | 2.3M | 2.2M | |
Short Term Investments | 54.4M | 149.7M | 106.5M | 22.5M | 73.9M | 64.8M | |
Net Tangible Assets | (48.5M) | 145.4M | 61.4M | (38.0M) | (43.7M) | (41.5M) | |
Retained Earnings Total Equity | (358.0M) | (391.2M) | (384.2M) | (447.8M) | (403.0M) | (423.1M) | |
Long Term Debt Total | 115.7M | 121.7M | 128.2M | 142.4M | 163.8M | 171.9M | |
Capital Surpluse | 433.8M | 434.4M | 566.9M | 549.3M | 631.8M | 491.4M |
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Avadel Pharmaceuticals using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Avadel Pharmaceuticals PLC. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Avadel Pharmaceuticals information on this page should be used as a complementary analysis to other Avadel Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Complementary Tools for Avadel Stock analysis
When running Avadel Pharmaceuticals' price analysis, check to measure Avadel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Avadel Pharmaceuticals is operating at the current time. Most of Avadel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Avadel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Avadel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Avadel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum |
Is Avadel Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avadel Pharmaceuticals. If investors know Avadel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avadel Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Revenue Per Share 0.633 | Quarterly Revenue Growth (1.00) | Return On Assets (0.55) | Return On Equity (7.80) |
The market value of Avadel Pharmaceuticals is measured differently than its book value, which is the value of Avadel that is recorded on the company's balance sheet. Investors also form their own opinion of Avadel Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Avadel Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avadel Pharmaceuticals' market value can be influenced by many factors that don't directly affect Avadel Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avadel Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avadel Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avadel Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.